Last reviewed · How we verify
Iodixanol (Visipaque)
Iodixanol is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and organs during diagnostic imaging procedures.
Iodixanol is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and organs during diagnostic imaging procedures. Used for Coronary angiography and percutaneous coronary intervention, Peripheral vascular angiography, Renal artery imaging.
At a glance
| Generic name | Iodixanol (Visipaque) |
|---|---|
| Also known as | Visipaque |
| Sponsor | Chinese PLA General Hospital |
| Drug class | Non-ionic iso-osmolar contrast medium |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging / Radiology |
| Phase | FDA-approved |
Mechanism of action
Iodixanol contains iodine atoms that absorb X-rays, creating contrast between tissues of different densities. As an iso-osmolar contrast medium (osmolality ~290 mOsm/kg, matching blood), it is designed to minimize osmotic stress on cells and reduce nephrotoxicity compared to hyperosmolar contrast agents. It is used intravenously during angiography, coronary interventions, and other vascular imaging procedures.
Approved indications
- Coronary angiography and percutaneous coronary intervention
- Peripheral vascular angiography
- Renal artery imaging
- General vascular and cardiac imaging procedures
Common side effects
- Contrast-induced nephropathy (acute kidney injury)
- Allergic reactions (rash, urticaria)
- Nausea and vomiting
- Hypersensitivity reactions
- Bradycardia
Key clinical trials
- Evaluation of the Efficacy of Suprascapular Nerve Block in Adhesive Capsulitis (NA)
- Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma (NA)
- Intra-discal Steroid Injection for MODIC I Discopathy (PHASE4)
- Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material (PHASE4)
- Effect of Evolocumab on Coronary Atherosclerosis (PHASE3)
- Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes (PHASE1)
- Correlation Between Computer Tomography Angiography and D-Dimer Level for the Diagnosis of Pulmonary Embolism
- Pediatric Risk of Hypothyroidism With Iodinated Contrast Media (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iodixanol (Visipaque) CI brief — competitive landscape report
- Iodixanol (Visipaque) updates RSS · CI watch RSS
- Chinese PLA General Hospital portfolio CI